Better Buy: Moderna vs. Axsome Therapeutics
Moderna (NASDAQ: MRNA) soared to fame in the early days of the pandemic thanks to its coronavirus vaccine. The stock price followed -- ending 2020 with a 434% gain. Since then, though, interest in vaccine stocks has waned. And Moderna shares have suffered.
At the same time, fellow biotech company Axsome Therapeutics (NASDAQ: AXSM) is getting its moment in the spotlight. Axsome shares have defied the bear market so far. That's as the company launches its very first products.
Regardless of recent stock performance, both companies offer solid future prospects. Now the question is: Which of these dynamic biotech players makes the better buy today?
Source Fool.com
